Compare BZUN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | RCEL |
|---|---|---|
| Founded | 2007 | N/A |
| Country | China | United States |
| Employees | 6762 | 226 |
| Industry | Catalog/Specialty Distribution | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 146.2M |
| IPO Year | N/A | N/A |
| Metric | BZUN | RCEL |
|---|---|---|
| Price | $2.90 | $7.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | ★ 240.6K | 220.7K |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.89 | $17.17 |
| Revenue Next Year | $6.16 | $49.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.07 | $3.22 |
| 52 Week High | $4.88 | $7.12 |
| Indicator | BZUN | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 54.38 |
| Support Level | $2.61 | $3.92 |
| Resistance Level | $3.04 | $5.18 |
| Average True Range (ATR) | 0.13 | 0.30 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 64.87 | 44.50 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.